Summaries for Patients |

Drug Treatment for Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians FREE

[+] Article, Author, and Disclosure Information

The summary below is from the full report titled “Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians.” It is in the 16 September 2008 issue of Annals of Internal Medicine (volume 149, pages 404-415). The authors are A. Qaseem, V. Snow, P. Shekelle, R. Hopkins Jr., M.A. Forciea, and D.K. Owens, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians.

Ann Intern Med. 2008;149(6):I-46. doi:10.7326/0003-4819-149-6-200809160-00002
Text Size: A A A

Who developed these guidelines?

The American College of Physicians (ACP) developed these recommendations. Members of the ACP are internists—specialists in the care of adults.

What is the problem and what is known about it so far?

As people get older, their bones become less dense and can break (fracture) more easily—conditions known as osteopenia (mild bone loss) and osteoporosis (severe bone loss). Osteoporosis is especially common in women after menopause, but men get it, too. Other factors that increase osteoporosis are smoking, alcohol, low intake of calcium and vitamin D, lack of exercise, white ethnicity, low body weight, a family history of osteoporosis, certain drugs (especially corticosteroids), thyroid disease, and possibly caffeine.

Testing for osteoporosis involves a test called dual-energy x-ray absorptiometry (DXA) that uses x-ray beams to measure soft tissue and bone thickness. Newer tests involve the use of other x-ray techniques and ultrasonography.

Drugs can slow bone loss and have been used to prevent or treat osteopenia and osteoporosis. These drugs include bisphosphonates, estrogens and drugs that affect estrogen receptors, calcitonin, and teriparitide. Although they are dietary supplements, not drugs, vitamin D and calcium supplements can also prevent bone loss. However, drugs have side effects and cost money. Doctors and patients must weigh the benefits and harms when deciding whether to use them to prevent fractures related to low bone density.

How did the ACP develop these recommendations?

The guideline authors reviewed published research to determine the benefits and harms of using drugs to prevent fractures in men and women with low bone density. They also looked for studies that compared one drug with another to see whether certain drugs provided more benefit or harm than others.

What did the authors find?

Good evidence shows that bisphosphonates reduce fractures, but good information is lacking on how long people should take these drugs. The most common side effect with bisphosphonates is stomach upset, but a rare and more serious event involves breakdown of the jawbone. Estrogens prevent fractures but can increase the risk for certain types of cancer, stroke, and blood clots. Studies show that drugs that work on estrogen receptors decrease spine fractures (but not hip fractures) and have no serious side effects. Fair to good information shows that calcitonin and teriparatide reduce spine fractures, but calcitonin does not reduce other types of fractures; neither drug has serious side effects. It is unclear how effectively calcium or vitamin D alone can prevent fractures, but taking both together reduces fractures. No good evidence proves that one drug is better than the others.

What does the ACP suggest that patients and doctors do?

First, doctors should offer drugs to prevent fractures to adults who are known to have osteoporosis by testing or who have previously experienced a fragility fracture (a fracture that occurred without significant trauma). Second, doctors and patients should consider drug treatment to prevent fracture in adults who are at risk for osteoporosis. Finally, doctors and patients should choose from among the available drugs on the basis of each patient's risks and preferences.

What are the cautions related to these recommendations?

The recommendations may change as new studies are done.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.